The approval of Waskyra for Wiskott–Aldrich syndrome demonstrates that gene therapies can successfully reach regulatory approval when developed by non-profit organizations. This milestone may accelerate future therapeutic innovation, broaden investment in rare disease research, and expand access to curative-intent treatments for underserved patient populations.

New research on "jumping genes" could lead to safer, more precise gene-editing techniques.